Nicholas Everett
No más puestos en curso
Perfil
Nicholas Everett worked as a Chief Scientist-Drug Discovery at American Bioscience, Inc., Abraxis BioScience, Inc. (2006-2007), and Polimeri Europa Americas, Inc. (1987-1991).
He also worked as a Research Scientist at Stauffer Chemical Co. (1981-1987).
Dr. Everett received his undergraduate degree from the University of London and his doctorate from the University of Leicester.
Antiguos cargos conocidos de Nicholas Everett.
| Empresas | Cargo | Fin |
|---|---|---|
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Director Técnico/Científico/I+D | 30/03/2011 |
Abraxis BioScience, Inc. /Old/
 Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Director Técnico/Científico/I+D | 01/11/2007 |
| Polimeri Europa Americas, Inc. | Corporate Officer/Principal | 01/03/1991 |
| Stauffer Chemical Co. | Director Técnico/Científico/I+D | 01/03/1987 |
| American Bioscience, Inc. | Director Técnico/Científico/I+D | - |
Formación de Nicholas Everett.
| University of London | Undergraduate Degree |
| University of Leicester | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
| American Bioscience, Inc. | Health Technology |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Health Technology |
| Stauffer Chemical Co. | Process Industries |
| Polimeri Europa Americas, Inc. |
- Bolsa de valores
- Insiders
- Nicholas Everett
